Table 2.

Characteristics of USTE and VEDO observations

Observationsa	USTE (N = 282)	Unavailable observations N (proportion) ‡	VEDO (N = 359)	Unavailable observations N (proportion) ‡
Trough level (μg/mL; median, IQR)	11.6 (5.9–17)	0 ‡	25.9 (16.4–35.1)	0‡
Drug antibodies (AU/mL; median, IQR)	0 (0–0.1)	0 ‡	0 (0–0.2)	2 (0.01)‡
Drug antibodies positive (N, proportion)	5 (0.02)	0	16 (0.05)	2 (0.01)
Intensified treatment (N, proportion)	64 (0.23)	116 (0.41)	112 (0.31)	75 (0.21)
Induction treatment (N, proportion)	33 (0.12)	0	81 (0.23)	4 (0.01)
Length of the treatment (days; median, IQR)	350 (165–678)	0 ‡	307 (95–672)	4 (0.01) ‡
Subcutaneous application (N, proportion)	NA		22 (0.06)	75 (0.21)
F-CPT (μg/g; median, IQR)	398 (68.3–1400)	0 ‡	257 (39–1050)	0 ‡
CRP (mg/L; median, IQR)	1 (0.5–5.6)	116 (0.41) ‡	0.85 (0.5–2.63)	75 (0.21) ‡
ESR (mm/h; median, IQR)	10 (5–20)	145 (0.51) ‡	12 (8–20)	154 (0.43) ‡
Concomitant treatment
Azathioprine (N, proportion)	31 (0.11)	116 (0.41)	119 (0.33)	75 (0.21)
Methotrexate (N, proportion)	3 (0.01)	116 (0.41)	54 (0.15)	75 (0.21)
Steroids (N, proportion)	6 (0.02)	116 (0.41)	20 (0.06)	75 (0.21)
Antibiotics (N, proportion)	1 (0)	116 (0.41)	24 (0.07)	75 (0.21)
Exclusive enteral nutrition (N, proportion)	0 (0)	116 (0.41)	1 (0)	75 (0.21)

CRP C-reactive protein; ESR erythrocyte sedimentation rate; F-CPT faecal calprotectin; IQR interquartile range; N number; NA not applicable; USTE ustekinumab; VEDO vedolizumab; y year

^aMissing data during some observations are owing to the fact that not all drug applications were accompanied by full outpatient visit. Thus, in some observations, only trough levels, drug antibodies and faecal calprotectin levels were tested

‡ In case that variables are listed as (median, IQR), the number of observations with missing data for the respective variable is listed